Untitled (940 × 500 px) (200 × 200 px) (200 × 100 px) (1)

Experts Weigh In: GLP-1 Drugs, Mental Health, and Importance of Behaviour Change Programmes

Facing the rising tide of metabolic conditions, including obesity, worldwide, we now have GLP-1 drugs rewriting healthcare rules. Join our expert panel for a 60-minute interactive discussion where we'll explore the broader implications of obesity, the dual clinical and financial aspects of GLP-1s, and the impact on mental health for employers, health plans, and consultants. Earn 1 SHRM PDC Credit for attending.

In this GLP-1 webinar

With this new and promising class of GLP-1 drugs comes a series of critical considerations and questions for HR decision-makers, consultants, and health plans as to how you will address obesity in your strategic benefit plan offering. These considerations cover a wide range of aspects, including clinical, financial, and outcome-related factors, and expand beyond traditional healthcare benefits to create an inclusive and supportive environment for all employees. 

One Hour, Countless Insights 

Join us for a 60-minute interactive discussion - Experts Weigh In: GLP-1 Drugs, Mental Health, and Behaviour Change - Thursday, September 14, at 7pm BST / 8pm CEST / 2pm ET.

This event will explore complex health concepts in an accessible way, covering topics such as the broader implications of obesity, the dual clinical and financial aspects of GLP-1 drugs, and the impact of obesity and weight loss on mental health. We'll also discuss the importance of evidence-based behaviour-change programmes, which are key for organisations striving to achieve long-term clinical outcomes while remaining cost-effective. This holistic perspective on wellbeing is crucial for organisations looking to improve the health of their population and achieve cost savings. 

Benefit from Direct Access to Industry Experts 

To maximise your experience, our panel of clinical experts will dedicate time to addressing your pressing questions and offer guidance to help you confidently make informed decisions.  

Key Benefits for Attendees 

  • Equip yourself with the latest, data-driven knowledge on GLP-1 drugs and the connection between obesity, mental health, and overall wellbeing 
  • Learn about targeted strategies to support lifestyle and behaviour change, boosting long-term clinical outcomes and cost savings 
  • Walk away with personalised insights with clinical experts answering your questions 

Clinical Expert Panel 

  • Jeff Jacques, MD, chief medical officer, Virgin Pulse 
  • David Katz, MD, MPH, FACPM, FACP, FACLM, member of Virgin Pulse Advisory Council and CEO of Diet ID 
  • Dr. Kate Daley, head of psychology, Unmind 

Confirm your participation today and shape the future of workplace health – one where your employees thrive, becoming the healthiest versions of themselves through clinical outcomes that deliver return and value on investment. 

Can't attend live? Register and we'll send you the recording.

Thurs, Sept 14, at 7pm BST / 8pm CEST / 2pm ET

Additional resources you might like